RediClinic Reports 26x Revenue Growth in Eight Months, Sets D2C Market Benchmark
RediClinic, a Hyderabad-based natural supplement startup, has achieved 26 times revenue growth within eight months, setting a new benchmark in India's direct-to-consumer (D2C) nutraceutical market. Without external investment, the brand focuses on delivering effective supplements, notably its flagship product Diacontrol, gaining popularity in tier 1 and tier 2 cities. With a current valuation of 60 crore INR, RediClinic aims to surpass 100 crore INR by next financial year, competing with established players like Dabur and Wellbeing Nutrition through targeted marketing and consumer engagement.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (85/100). Lens Score 31/100.
Outlets measured: businessstandard, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (85–85/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 6 Oct, 11:10 am. Other outlets followed.